Lauren Boreta1, Adam J Gadzinski2, Susan Y Wu1, Melody Xu1, Kirsten Greene2, Kathryn Quanstrom2, Hao G Nguyen2, Peter R Carroll3, Thomas A Hope4, Felix Y Feng5. 1. Department of Radiation Oncology, University of California, San Francisco, CA. 2. Department of Urology, University of California, San Francisco, CA. 3. Department of Urology, University of California, San Francisco, CA; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. 4. University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA; Department of Radiology, San Francisco VA Medical Center, San Francisco, CA. 5. Department of Radiation Oncology, University of California, San Francisco, CA; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Electronic address: Felix.feng@ucsf.edu.
Abstract
OBJECTIVE: To identify locations of recurrence after radical prostatectomy (RP) with prostate-specific antigen (PSA) <2 by Gallium-68 prostate-specific membrane antigen (PSMA)-11 Positron Emission Tomography (PET) imaging, and to determine whether standard nodal radiation fields would cover the location of prostate cancer recurrence. MATERIALS AND METHODS: We performed a retrospective review of patients with PSMA-PET imaging for biochemical recurrence following RP with PSA ≤2.0 ng/mL and assessed if the recurrent disease was within standard radiation target volumes. We compared patient and clinical variables between men with recurrences covered by standard salvage radiation fields and those with recurrences outside of standard fields. RESULTS: We identified 125 patients for study inclusion. The median PSA at imaging was 0.40 ng/mL (interquartile range 0.28-0.63). PSMA-avid disease was found in 66 patients (53%). Of these, 25 patients (38%) had PSMA-avid lesions found outside of the pelvis, 33 (50%) had lesions confined to the pelvic lymph nodes and prostate bed, and 8 (12%) men had PSMA-avid recurrence only in the prostate bed. Salvage radiation including standard Intensity Modulated Radiation Therapy (IMRT) pelvic nodal volumes would not cover PSMA-avid nodal disease in 38 men (30%). PSA at the time of imaging was statistically associated with having PSMA-avid disease outside of standard nodal fields (P <.01). CONCLUSION: The 68Ga-PSMA-11 PET detects disease in a majority of patients with PSA ≤2.0 following RP. Nearly one-third of men had PSMA-avid disease that would be missed by standard radiation fields. This imaging modality may dramatically impact the design and use of post-RP salvage radiotherapy.
OBJECTIVE: To identify locations of recurrence after radical prostatectomy (RP) with prostate-specific antigen (PSA) <2 by Gallium-68 prostate-specific membrane antigen (PSMA)-11 Positron Emission Tomography (PET) imaging, and to determine whether standard nodal radiation fields would cover the location of prostate cancer recurrence. MATERIALS AND METHODS: We performed a retrospective review of patients with PSMA-PET imaging for biochemical recurrence following RP with PSA ≤2.0 ng/mL and assessed if the recurrent disease was within standard radiation target volumes. We compared patient and clinical variables between men with recurrences covered by standard salvage radiation fields and those with recurrences outside of standard fields. RESULTS: We identified 125 patients for study inclusion. The median PSA at imaging was 0.40 ng/mL (interquartile range 0.28-0.63). PSMA-avid disease was found in 66 patients (53%). Of these, 25 patients (38%) had PSMA-avid lesions found outside of the pelvis, 33 (50%) had lesions confined to the pelvic lymph nodes and prostate bed, and 8 (12%) men had PSMA-avid recurrence only in the prostate bed. Salvage radiation including standard Intensity Modulated Radiation Therapy (IMRT) pelvic nodal volumes would not cover PSMA-avid nodal disease in 38 men (30%). PSA at the time of imaging was statistically associated with having PSMA-avid disease outside of standard nodal fields (P <.01). CONCLUSION: The 68Ga-PSMA-11 PET detects disease in a majority of patients with PSA ≤2.0 following RP. Nearly one-third of men had PSMA-avid disease that would be missed by standard radiation fields. This imaging modality may dramatically impact the design and use of post-RP salvage radiotherapy.
Authors: Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter Journal: Am J Nucl Med Mol Imaging Date: 2020-12-15
Authors: Elisa Perry; Arpit Talwar; Kim Taubman; Michael Ng; Lih-Ming Wong; Russell Booth; Tom R Sutherland Journal: Eur J Nucl Med Mol Imaging Date: 2021-01-05 Impact factor: 9.236
Authors: Henk B Luiting; Pim J van Leeuwen; Martijn B Busstra; Tessa Brabander; Henk G van der Poel; Maarten L Donswijk; André N Vis; Louise Emmett; Phillip D Stricker; Monique J Roobol Journal: BJU Int Date: 2019-11-29 Impact factor: 5.588
Authors: Shafak Aluwini; Daniela E Oprea-Lager; Hilda de Barros; Niven Mehra; Herman Stoevelaar; Derya Yakar; Henk van der Poel Journal: BJUI Compass Date: 2021-02-03